Rocket Pharmaceuticals (RCKT) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts RCKT Hot Sheet
Join SI Premium – FREE
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.62), $0.10 better than the analyst estimate of ($0.72).
For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia Extends Decline To 7.3%, Biggest Drop Since April 2025
- Ralph Lauren (RL) Tops Q2 EPS by 41c
- IREN Limited (IREN) call put ratio 1.5 calls to 1 put as share price down 15.7%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
